Oncolytics Announces First Stage of Metastatic Melanoma Phase 2 Trial Meets Primary Endpoint
May 22, 2013 at 06:41 AM EDT
Oncolytics Biotech Inc. ("Oncolytics") (NASDAQ: ONCY ) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator
